Key Takeaways
- The FDA approved Lipfendra (enlicitide) on July 17, 2026, the first PCSK9 inhibitor you swallow instead of inject, a once-daily pill from Merck.
- In the phase 3 CORALreef trials it cut LDL cholesterol by about 56% on top of statins, landing in the same territory as injectable PCSK9 drugs.
- The real advance is not raw potency, it is the format: a room-temperature tablet instead of a refrigerated shot, which is what usually decides whether patients stay on a cholesterol drug at all.
The class that finally got a pill
PCSK9 inhibitors are some of the strongest LDL-lowering drugs we have. They have also, until now, all come with a needle. Repatha, Praluent, Leqvio, all of them are injections, some every two weeks, some twice a year, all needing to live in a fridge. For a lot of patients that is enough friction to skip doses or never start.
So the headline on Lipfendra is not that it invented a new way to lower cholesterol. It is that it delivered a known, powerful mechanism in a form people will actually take, a daily tablet. That is a bigger deal than it sounds for a disease treated over decades.
How enlicitide works
Picture the liver as the body’s cholesterol cleanup crew. Its cells bristle with LDL receptors that grab bad cholesterol out of the blood and haul it in to be broken down. A protein called PCSK9 sabotages that crew: it latches onto the receptors and marks them for destruction, so the liver clears less and less LDL and blood levels climb.
Enlicitide, the active drug in Lipfendra, is a macrocyclic peptide, an unusually large molecule to survive as an oral pill, that binds PCSK9 and blocks it from tagging the receptors. The receptors stick around, keep recycling, and keep pulling LDL out of circulation. That is the same endpoint the injectable antibodies reach, arrived at through a swallowed drug rather than one under the skin.
What the CORALreef trials showed
| Detail | Value |
|---|---|
| Drug | Lipfendra (enlicitide), Merck, once-daily oral |
| Class | First oral PCSK9 inhibitor |
| Trials | CORALreef Lipids and CORALreef HeFH (phase 3) |
| LDL reduction | ~56% vs placebo at week 24, on top of statins |
| Safety | Adverse events comparable to placebo |
| Approved | July 17, 2026 |
| Indication | Adults with high LDL, including HeFH |
Both CORALreef studies were randomized, double-blind, and placebo-controlled, run in adults already taking the highest statin dose they could tolerate. On that background, adding Lipfendra dropped LDL by roughly 56% against placebo at 24 weeks. Side effects tracked with placebo, and no new safety flags turned up in the reported data.
Where it fits against what we already have
Oral cholesterol drugs already exist, they just do not hit this hard. Statins, the first-line workhorses, lower LDL somewhere around 35% to 50%. Ezetimibe, which blocks cholesterol absorption in the gut, adds a modest 15% to 20%. Bempedoic acid sits in between. None of them reach PCSK9-inhibitor depth.
Lipfendra collapses the old trade-off, injectable-level LDL lowering without the injection. For someone with stubbornly high LDL or an inherited condition like HeFH who has maxed out statins and balked at shots, that is a genuinely new option. The long-term question, whether the LDL drop translates into fewer heart attacks and strokes over years, is the one cardiovascular outcome trials still have to answer, as they did for the injectables.
Sources:
- Medical News Today, “New cholesterol pill Lipfendra gets FDA approval”
- FDA, “FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol”
- TCTMD, “FDA Approves Enlicitide, Oral PCSK9 Inhibitor, for LDL-Lowering”
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.